Inventor

Stephen D. Gillies

Inventor

Carlisle, MA, US

Overview

1987–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 70 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides30%

A61KPreparations for medical, dental or toiletry purposes25%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%

C12NMicroorganisms or enzymes11%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests5%

C12YEnzymes2%

G01NInvestigating or analysing materials by determining their chemical or physical properties2%

C07DHeterocyclic compounds0%

PatentTitleYear

11,045,533Humanized antibodies2021 10,633,452Anti-cancer antibodies with reduced complement fixation2020 10,603,367Humanized antibodies2020 10,604,576Antibodies and immunocytokines2020 10,017,579Anti-cancer antibodies with reduced complement fixation2018 9,957,323Anti-ICOS antibodies2018 9,617,338'Antibodies and immunocytokines'2017 9,617,349'Anti-cancer antibodies with reduced complement fixation'2017 9,567,399'Antibodies and immunocytokines'2017 9,522,956'Combination therapy using anti-EGFR and anti-HER2 antibodies'2016 8,926,973'Reducing the immunogenicity of fusion proteins'2015 8,835,606'Anti-cancer antibodies with reduced complement fixation'2014 8,703,908'Expression and export of angiogenesis inhibitors as immunofusins'2014 8,557,232'Stabilization of Fc-interferon-beta fusion proteins'2013 8,470,991'Immunocytokine sequences and uses thereof'2013 8,420,087'Interleukin-12 targeted to oncofoetal fibronectin'2013 8,337,844'CD20-binding polypeptide compositions for treating autoimmune disease'2012 8,338,575'IL-7 fusion proteins'2012 8,206,718'Expression and export of angiogenesis inhibitors as immunofusins'2012 8,147,832'CD20-binding polypeptide compositions and methods'2012 8,066,994'Proteins comprising an IgG2 domain'2011 8,043,608'Methods of using Fc-cytokine fusion proteins'2011 7,973,150'Reducing the immunogenicity of fusion proteins'2011 7,960,514'IL-7 fusion proteins'2011 7,955,590'Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens'2011 7,888,071'DNA encoding IL-2 fusion proteins with modulated selectivity'2011 7,879,319'Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation'2011 7,833,976'Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies'2010 7,803,618'Recombinant tumor specific antibody and use thereof'2010 7,790,415'Enhancing the circulating half-life of antibody-based fusion proteins'2010 7,767,405'Immunocytokine sequences and uses thereof'2010 7,670,595'Fc-interferon-beta fusion proteins'2010 7,615,217'Artificial proteins with reduced immunogenicity'2009 7,601,814'Reducing the immunogenicity of fusion proteins'2009 7,589,179'IL-7 variants with reduced immunogenicity'2009 7,582,288'Methods of targeting multiple cytokines'2009 7,576,193'Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation'2009 7,517,526'Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents'2009 7,507,406'Enhancing the circulating half-life of antibody-based fusion proteins'2009 7,465,447'Fc-erythropoietin fusion protein with improved pharmacokinetics'2008 7,462,350'Cancer treatments including administering IL-2 fusion proteins with modulated selectivity'2008 7,459,538'Recombinant tumor specific antibody and use thereof'2008 7,432,357'Anti-cancer antibodies with reduced complement fixation'2008 7,365,054'Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies'2008 7,323,549'IL-7 fusion proteins'2008 7,226,998'Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation'2007 7,189,830'Anti-KSA/IL-2 fusion proteins with reduced immunogenicity'2007 7,186,804'IL-2 fusion proteins with modulated selectivity'2007 7,169,904'Immunocytokine sequences and uses thereof'2007 7,148,321'Expression technology for proteins containing a hybrid isotype antibody moiety'2006 7,141,651'Multiple cytokine protein complexes'2006 7,115,261'Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies'2006 7,091,321'Enhancing the circulating half-life of antibody-based fusion proteins'2006 7,067,110'Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens'2006 6,992,174'Reducing the immunogenicity of fusion proteins'2006 6,969,517'Recombinant tumor specific antibody and use thereof'2005 6,838,260'Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation'2005 6,617,135'Multiple cytokine protein complexes'2003 6,384,032'Inhibitors of IL-12 production'2002 5,880,146'Inhibition of IL-12-induced IFN-.gamma. synthesis by specific bis-phenol compounds as a method of immune modulation'1999 5,741,682'Expression induction method'1998 5,726,044'Expression and export technology of proteins as immunofusins'1998 5,665,578'Vector and method for achieving high level of expression in eukaryotic cells'1997 5,650,150'Recombinant antibody cytokine fusion proteins'1997 5,589,510'Method for inhibiting retroviral infection by administering a naphthalenesulfonic acid compound'1996 5,541,087'Expression and export technology of proteins as immunofusins'1996 5,338,669'Method of producing fusion proteins'1994 5,196,320'Method of producing engineered binding proteins'1993 5,149,635'Messenger RNA stabilization in animal cells'1992 4,663,281'Enhanced production of proteinaceous materials in eucaryotic cells'1987

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1987–1997Based in Scituate, MA, US· patent location history

1992–1998Patents assigned to ABBOTT BIOTECH INC (4)· patent assignee history

1993–1998Based in Hingham, MA, US· patent location history

1998–2021Based in Carlisle, MA, US· patent location history

2003–2010Patents assigned to EMD LEXIGEN RES CT CORP (15)· patent assignee history

2007–2020Patents assigned to MERCK PATENT GMBH (33)· patent assignee history

2011–2015Patents assigned to GILLIES STEPHEN D (10)· patent assignee history

2011–2014Patents assigned to LO KIN-MING (6)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
MERCK PATENT GMBH	33	2007–2020
EMD LEXIGEN RES CT CORP	15	2003–2010
GILLIES STEPHEN Dself	10	2011–2015
LO KIN-MING	6	2011–2014
ABBOTT BIOTECH INC	4	1992–1998

Locations

Location	Patents	Span
Carlisle, Massachusetts, US	61	1998–2021
Hingham, Massachusetts, US	6	1993–1998
Scituate, Massachusetts, US	3	1987–1997